| BMC Rheumatology | |
| The Joint Vasculitis Registry in German-speaking countries (GeVas) – a prospective, multicenter registry for the follow-up of long-term outcomes in vasculitis | |
| article | |
| Iking-Konert, Christof1  Kaufmann, Margit2  Kötter, Ina3  Müller-Ladner, Ulf4  Magnus, T.1  Rech, Jürgen5  Schubach, Fabian2  Schulze-Koops, Hendrik6  Venhoff, Nils7  Wiech, Thorsten8  Villiger, Peter9  Wallmeier, Pia1  Lamprecht, Peter1,10  Arnold, Sabrina1,10  Adler, Sabine1,11  de Groot, Kirsten1  Hellmich, Bernhard1,12  Hoyer, Bimba F.1,13  Holl-Ulrich, Konstanze1,14  Ihorst, Gabriele2  | |
| [1] Universitätsklinikum Hamburg Eppendorf;Clinical Trials Unit, Faculty of Medicine, Medical Center – University of Freiburg, University of Freiburg;Universitätsklinikum Hamburg Eppendorf und Klinikum Bad Bramstedt;Abt. Rheumatologie und Klinische Immunologie;Department of Internal Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander University (FAU) Erlangen-Nürnberg and Universitätsklinikum Erlangen;Division of Rheumatology and Clinical Immunology, Department of Internal Medicine IV, Ludwig-Maximilians-University Munich;Department of Rheumatology and Clinical Immunology, Faculty of Medicine, Medical Center – University of Freiburg, University of Freiburg;Institut für Pathologie, Universitätsklinikum Hamburg-Eppendorf;University Hospital and University of Bern;Department of Rheumatology and Clinical Immunology, University of Lübeck;SimZentrum Erfurt;Klinik für Innere Medizin, Rheumatologie und Immunologie medius KLINIK Kirchheim;Rheumatologie/klinische Immunologie und Exzellenzzentrum Entzündungsmedizin;Labor Lademannbogen MVZ GmbH | |
| 关键词: Vasculitis; GeVas; ANCA; Prospective; Registry; Giant cell arteritis; Long term; Outcome; Therapy; | |
| DOI : 10.1186/s41927-021-00206-2 | |
| 学科分类:社会科学、人文和艺术(综合) | |
| 来源: BioMed Central | |
PDF
|
|
【 摘 要 】
Vasculitides comprise a group of rare diseases which affect less than 5 in 10.000 individuals. Most types of vasculitis can become organ- and life-threatening and are characterized by chronicity, high morbidity and relapses, altogether resulting in significant morbidity and mortality. Previous studies have been either monocentric or mainly retrospective – studies with a prospective design mostly consisted of rather small cohorts of 100 to 200 patients. The aim of the Joint Vasculitis Registry in German-speaking countries (GeVas) is to record all patients who have been recently diagnosed with vasculitis or who have changed their treatment due to a relapse (inception cohort). In GeVas, data are collected prospectively in a multicenter design in Germany, Austria and Switzerland. By this approach, courses of vasculitis and their outcomes can be monitored over an extended period. GeVas is a prospective, web-based, multicenter, clinician-driven registry for the documentation of organ manifestations, damage, long-term progress and other outcomes of various types of vasculitis. The registry started recruiting in June 2019. As of October 2020, 14 centers have been initiated and started recruiting patients in Germany. Involvement of sites in Austria and the German-speaking counties of Switzerland is scheduled in the near future. In June 2019, we successfully established a prospective multicenter vasculitis registry being the first of its kind in German-speaking countries. The participating centers are currently recruiting, and systematic analysis of long-term vasculitis outcomes is expected in the ensuing period. German Clinical Trials Register (Deutsches Register Klinischer Studien): DRKS00011866 . Registered 10 May 2019.
【 授权许可】
CC BY|CC0
【 预 览 】
| Files | Size | Format | View |
|---|---|---|---|
| RO202108140002953ZK.pdf | 567KB |
PDF